NEW YORK (GenomeWeb News) – The Sanford-Burnham Medical Research Institute said today that its investigators will collaborate with Pfizer to identify therapeutic targets for use in preventing and treating complications related to obesity and diabetes.

Under the three-year collaboration, the partners at Pfizer and Sanford-Burnham's Conrad Prebys Center for Chemical Genomics will use novel screening tools and systems biology approaches to develop treatment methods for reducing insulin resistance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.